Centessa Pharmaceuticals PLC ADR

NASDAQ CNTA

Data sourced from

and

Daily

Download Data

Centessa Pharmaceuticals PLC ADR Market Capitalization on June 03, 2024: USD 854.10 M

Centessa Pharmaceuticals PLC ADR Market Capitalization is USD 854.10 M on June 03, 2024, a 99.21% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Centessa Pharmaceuticals PLC ADR 52-week high Market Capitalization is USD 1.17 B on March 22, 2024, which is 37.55% above the current Market Capitalization.
Centessa Pharmaceuticals PLC ADR 52-week low Market Capitalization is USD 428.73 M on June 05, 2023, which is -49.80% below the current Market Capitalization.
Centessa Pharmaceuticals PLC ADR average Market Capitalization for the last 52 weeks is USD 764.55 M.

NASDAQ: CNTA

Centessa Pharmaceuticals PLC ADR

CEO	Dr. Saurabh Saha M.D., Ph.D.
IPO Date	May 28, 2021
Location	United Kingdom
Headquarters	1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
Employees	77
Sector	Healthcare
Industry	Biotechnology

Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Key trends